Related Experiment Video
Updated: Apr 13, 2026
12:10
Retzius-Sparing Robot-Assisted Radical Prostatectomy
Published on: May 19, 2022
10.0K
Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of
Ashley E Ross1, Kasra Yousefi2, Elai Davicioni2
1James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
European Urology
|April 30, 2015
Summary
Risk models can help guide prostate cancer treatment decisions after surgery, reducing overtreatment for men with adverse pathologic features (APFs). These models are less effective for patients who experience biochemical recurrence (BCR).
Area of Science:
- Urology
- Oncology
- Medical Decision Making
Background:
- Adjuvant radiation therapy is often recommended for men with adverse pathologic features (APFs) after radical prostatectomy (RP).
- This study evaluates men treated with RP alone until metastasis to assess treatment decision-making tools.
Purpose of the Study:
- To determine if clinicopathologic risk models can effectively guide postoperative therapeutic decisions for prostate cancer patients.
- To evaluate the performance of risk models in predicting metastasis and recurrence.
Main Methods:
- Analysis of 3089 men with intermediate- or high-risk prostate cancer undergoing RP.
- Inclusion criteria: undetectable post-surgery PSA and no prior therapy before metastasis.
- Adverse pathologic features (APFs) defined as pT3 disease or positive surgical margins.
- Statistical analysis included AUC for risk factor discrimination and competing risks analysis for metastasis and BCR.
Main Results:
- 43% of the cohort had APFs; 6% experienced metastasis within 10 years post-RP.
- Men with APFs had a 7.5% cumulative incidence of metastasis at 10 years.
- Risk models (CAPRA-S, Eggener) showed good discrimination for metastasis prediction (AUC ~0.8) in the APF population.
- Model performance decreased significantly for predicting metastasis after biochemical recurrence (BCR).
Conclusions:
- Clinicopathologic risk models can aid in guiding adjuvant therapy decisions post-RP, potentially reducing overtreatment.
- Utilizing risk model cut points could spare a significant percentage of men from unnecessary treatment.
- Risk model utility is diminished in patients who have already experienced BCR.
Related Concept Videos
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
565
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
565
01:21Cancer Survival Analysis
846
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
846
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
85
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
85
01:20Comparing the Survival Analysis of Two or More Groups
720
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
720